Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of double-blind randomized controlled trials
PubMed 27103682 · doi:10.1192/bjp.bp.114.160242
What was done
A systematic search and exploratory hypothesis-testing meta-analysis of double-blind RCTs published between January 1980 and July 2014 evaluating omega-3 highly unsaturated fatty acids (HUFAs) versus placebo for depression. The analysis included 35 RCTs with 6,665 participants receiving omega-3 HUFAs and 4,373 receiving placebo.
What was found
Among participants with diagnosed depression, EPA-predominant formulations (>50% EPA) demonstrated clinical benefit over placebo (Hedges' g = 0.61, P < 0.001), whereas DHA-predominant formulations (>50% DHA) showed no significant benefit. EPA failed to prevent depressive symptoms in populations without a baseline diagnosis of depression.
Why it matters
This review explains discrepancies in the omega-3 literature by demonstrating that therapeutic efficacy depends on using EPA-predominant formulations in clinically diagnosed populations rather than DHA-predominant preparations or preventative applications.
Limits
The meta-analysis relied on exploratory hypothesis testing across heterogeneous trials. Specific optimal dosages, treatment durations, and adverse event profiles were not detailed in the abstract.
Cited by
- supports EPA is uniquely effective compared to DHA for improving depression due to its anti-inflammatory effects.